A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders

David A. Geier, Janet K. Kern, Georgia Davis, Paul G. King, James Adams, John L. Young, Mark R. Geier

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: L-carnitine was proposed as a potential treatment for patients diagnosed with an autism spectrum disorder to improve mitochondrial dysfunction, but no prior randomized controlled trials have been conducted. Material/Methods: Thirty subjects diagnosed with an ASD were randomly assigned to receive a standardized regimen (50 mg L-carnitine/kg bodyweight/day) of liquid L-carnitine (n=19) or placebo (n=11) for 3-months. Measures included changes in professionally completed Childhood Autism Rating Scale (CARS), hand muscle testing, and modified clinical global impression (CGI) forms; parent completed Autism Treatment Evaluation Checklist (ATEC), treatment adherence measurement (TAM), frequency and intensity of side effect rating (FISER)/global rating of side effect burden (GRSEB)/patient report of incidence of side effects (PRISE) forms; and lab testing. Results: Significant improvements were observed in CARS (-2.03, 95% CI=-3.7 to -0.31), CGI (-0.69, 95% CI=-1.1 to -0.06), and ATEC scores. Significant correlations between changes in serum free-carnitine levels and positive clinical changes were observed for hand muscle strength (R2=0.23, P=0.046), cognitive scores (R2=0.27, P=0.019), and CARS scores (R2=0.20, P=0.047). Study subjects were protocol- compliant (average adherence was >85%) and generally well-tolerated the L-carnitine therapy given. Conclusions: L-carnitine therapy (50 mg/kilogram-bodyweight/day) administered for 3-months significantly improved several clinical measurements of ASD severity, but subsequent studies are recommended.

Original languageEnglish (US)
JournalMedical Science Monitor
Volume17
Issue number6
StatePublished - 2011

Fingerprint

Carnitine
Autistic Disorder
Randomized Controlled Trials
Checklist
Therapeutics
Muscle Strength
Hand Strength
Autism Spectrum Disorder
Hand
Placebos
Muscles
Incidence
Serum

Keywords

  • Autism spectrum disorder
  • Carnitine
  • Mitochondrial dysfunction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Geier, D. A., Kern, J. K., Davis, G., King, P. G., Adams, J., Young, J. L., & Geier, M. R. (2011). A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Medical Science Monitor, 17(6).

A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. / Geier, David A.; Kern, Janet K.; Davis, Georgia; King, Paul G.; Adams, James; Young, John L.; Geier, Mark R.

In: Medical Science Monitor, Vol. 17, No. 6, 2011.

Research output: Contribution to journalArticle

Geier, David A. ; Kern, Janet K. ; Davis, Georgia ; King, Paul G. ; Adams, James ; Young, John L. ; Geier, Mark R. / A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. In: Medical Science Monitor. 2011 ; Vol. 17, No. 6.
@article{91d7797976f6440a90e61e3561a79b55,
title = "A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders",
abstract = "Background: L-carnitine was proposed as a potential treatment for patients diagnosed with an autism spectrum disorder to improve mitochondrial dysfunction, but no prior randomized controlled trials have been conducted. Material/Methods: Thirty subjects diagnosed with an ASD were randomly assigned to receive a standardized regimen (50 mg L-carnitine/kg bodyweight/day) of liquid L-carnitine (n=19) or placebo (n=11) for 3-months. Measures included changes in professionally completed Childhood Autism Rating Scale (CARS), hand muscle testing, and modified clinical global impression (CGI) forms; parent completed Autism Treatment Evaluation Checklist (ATEC), treatment adherence measurement (TAM), frequency and intensity of side effect rating (FISER)/global rating of side effect burden (GRSEB)/patient report of incidence of side effects (PRISE) forms; and lab testing. Results: Significant improvements were observed in CARS (-2.03, 95{\%} CI=-3.7 to -0.31), CGI (-0.69, 95{\%} CI=-1.1 to -0.06), and ATEC scores. Significant correlations between changes in serum free-carnitine levels and positive clinical changes were observed for hand muscle strength (R2=0.23, P=0.046), cognitive scores (R2=0.27, P=0.019), and CARS scores (R2=0.20, P=0.047). Study subjects were protocol- compliant (average adherence was >85{\%}) and generally well-tolerated the L-carnitine therapy given. Conclusions: L-carnitine therapy (50 mg/kilogram-bodyweight/day) administered for 3-months significantly improved several clinical measurements of ASD severity, but subsequent studies are recommended.",
keywords = "Autism spectrum disorder, Carnitine, Mitochondrial dysfunction",
author = "Geier, {David A.} and Kern, {Janet K.} and Georgia Davis and King, {Paul G.} and James Adams and Young, {John L.} and Geier, {Mark R.}",
year = "2011",
language = "English (US)",
volume = "17",
journal = "Medical Science Monitor",
issn = "1234-1010",
publisher = "International Scientific Literature Inc.",
number = "6",

}

TY - JOUR

T1 - A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders

AU - Geier, David A.

AU - Kern, Janet K.

AU - Davis, Georgia

AU - King, Paul G.

AU - Adams, James

AU - Young, John L.

AU - Geier, Mark R.

PY - 2011

Y1 - 2011

N2 - Background: L-carnitine was proposed as a potential treatment for patients diagnosed with an autism spectrum disorder to improve mitochondrial dysfunction, but no prior randomized controlled trials have been conducted. Material/Methods: Thirty subjects diagnosed with an ASD were randomly assigned to receive a standardized regimen (50 mg L-carnitine/kg bodyweight/day) of liquid L-carnitine (n=19) or placebo (n=11) for 3-months. Measures included changes in professionally completed Childhood Autism Rating Scale (CARS), hand muscle testing, and modified clinical global impression (CGI) forms; parent completed Autism Treatment Evaluation Checklist (ATEC), treatment adherence measurement (TAM), frequency and intensity of side effect rating (FISER)/global rating of side effect burden (GRSEB)/patient report of incidence of side effects (PRISE) forms; and lab testing. Results: Significant improvements were observed in CARS (-2.03, 95% CI=-3.7 to -0.31), CGI (-0.69, 95% CI=-1.1 to -0.06), and ATEC scores. Significant correlations between changes in serum free-carnitine levels and positive clinical changes were observed for hand muscle strength (R2=0.23, P=0.046), cognitive scores (R2=0.27, P=0.019), and CARS scores (R2=0.20, P=0.047). Study subjects were protocol- compliant (average adherence was >85%) and generally well-tolerated the L-carnitine therapy given. Conclusions: L-carnitine therapy (50 mg/kilogram-bodyweight/day) administered for 3-months significantly improved several clinical measurements of ASD severity, but subsequent studies are recommended.

AB - Background: L-carnitine was proposed as a potential treatment for patients diagnosed with an autism spectrum disorder to improve mitochondrial dysfunction, but no prior randomized controlled trials have been conducted. Material/Methods: Thirty subjects diagnosed with an ASD were randomly assigned to receive a standardized regimen (50 mg L-carnitine/kg bodyweight/day) of liquid L-carnitine (n=19) or placebo (n=11) for 3-months. Measures included changes in professionally completed Childhood Autism Rating Scale (CARS), hand muscle testing, and modified clinical global impression (CGI) forms; parent completed Autism Treatment Evaluation Checklist (ATEC), treatment adherence measurement (TAM), frequency and intensity of side effect rating (FISER)/global rating of side effect burden (GRSEB)/patient report of incidence of side effects (PRISE) forms; and lab testing. Results: Significant improvements were observed in CARS (-2.03, 95% CI=-3.7 to -0.31), CGI (-0.69, 95% CI=-1.1 to -0.06), and ATEC scores. Significant correlations between changes in serum free-carnitine levels and positive clinical changes were observed for hand muscle strength (R2=0.23, P=0.046), cognitive scores (R2=0.27, P=0.019), and CARS scores (R2=0.20, P=0.047). Study subjects were protocol- compliant (average adherence was >85%) and generally well-tolerated the L-carnitine therapy given. Conclusions: L-carnitine therapy (50 mg/kilogram-bodyweight/day) administered for 3-months significantly improved several clinical measurements of ASD severity, but subsequent studies are recommended.

KW - Autism spectrum disorder

KW - Carnitine

KW - Mitochondrial dysfunction

UR - http://www.scopus.com/inward/record.url?scp=79958724983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958724983&partnerID=8YFLogxK

M3 - Article

VL - 17

JO - Medical Science Monitor

JF - Medical Science Monitor

SN - 1234-1010

IS - 6

ER -